We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals

News   Nov 26, 2015

 
ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals
 
 
 

RELATED ARTICLES

Are Regulations on Genetically Modified Organisms Holding Back Agricultural Innovation?

News

The EU's policy on genetically modified organisms (GMO's) is extremely strict and prevents new GMO crops from being authorized. The policy is based on arguments about the risk and unnaturalness of GMO plants - but these arguments cannot justify the restrictive regulation, three researchers conclude in a new study.

READ MORE

Drugs to Prevent Stroke and Dementia Show Promise in Early Trial

News

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study.

READ MORE

Novel Synthesis Strategy Speeds Up Identification of Simpler Versions of Natural Product

News

A new chemical synthesis strategy to harvest the rich information found in natural products has led to the identification of novel, simpler derivatives with potential to selectively protect neurons, important for neurodegenerative diseases like Alzheimer’s disease, or to prevent the body’s immune system from rejecting organ transplants, according to a Baylor University-led study.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE